

F  
1. A method to prepare an isolated nucleic acid molecule [comprising] having a nucleotide sequence encoding at least one of the variable regions of each of the  $\alpha$  and  $\beta$  chains of a non-human T-cell receptor (TCR) which TCR is specific for a tumor-associated antigen (TAA) selected from Her-2/neu, RAS, p53, tyrosinase, MART, Gp100, Mage, Bage and MUC-1, which method comprises

SUB  
G-2  
immunizing a transgenic non-human mammal species, which produce human HLA, with an effective amount of said TAA to produce HLA restricted cytotoxic T lymphocytes (CTL) which display TCR specific for said TAA in amounts sufficient to lyse tumor cells having the TAA,

recovering said HLA restricted CTL, which contain said nucleic acid molecules encoding at least one of each of the variable regions of the  $\alpha$  and  $\beta$  chains of a non-human TCR,

cloning or amplifying [a] said nucleic acid molecule encoding the TCR nucleotide sequence isolated from [an] the HLA restricted [cytotoxic T lymphocytes (CTL)] prepared by immunizing a transgenic non-human mammal [or avian] species, modified so as to express at least one human HLA antigen, with an effective amount of said TAA to produce the HLA restricted cytotoxic T lymphocytes which display TCR specific for said TAA in amounts sufficient to lyse tumor cells having the TAA and which contain said nucleic acid molecules], [therefrom] and

[isolating] recovering said receptor-encoding nucleic acid molecules [therefrom].

F2 SUB  
G-2  
5. (Amended) The method of claim 4 wherein said primers are [essentially as] set forth in Figure 6 (SEQ ID NOS: 3-42).

### REMARKS

Entry of the amendment is respectfully requested since it is responsive to points raised in the Final rejection and would reduce the issues on appeal.

Claims 1-5 are before the Examiner. Claim 6-21 remain withdrawn from consideration by the Examiner under Rule 142(b) as directed to a non-elected inventions. The election was made without traverse in paper No. 20.

Claims 1 and 5 have been amended to address issues raised in the Official Action. The product by process definition of the HLA restricted CTL has been avoided in the redrafting of the claim. Further, reference to avian transgenic species has been deleted to advance